Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370296 | 1.00 | CNR1 (0.47) | CNR1CHRNA7CNR2KDM4ENPC1 | |
| SCHEMBL5370292 | 1.00 | CNR1 (0.47) | CNR1CHRNA7CNR2KDM4ENPC1 | |
| SCHEMBL5339713 | 0.88 | CNR1 (0.50) | CNR1CHRNA7CNR2KDM4ENPC1 | |
| SCHEMBL6332827 | 0.83 | CNR1 (0.53) | CNR1CHRNA7CNR2KDM4ENPC1 | |
| SCHEMBL5350855 | 0.81 | CNR1 (0.56) | CNR1CHRNA7CNR2KDM4ENPC1 | |
| SCHEMBL739526 | 0.81 | CNR1 (0.64) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL4277527 | 0.80 | CNR1 (0.55) | CNR1CHRNA7CNR2KDM4ENPC1 | |
| SCHEMBL6357570 | 0.78 | CNR1 (0.57) | CNR1CNR2KDM4E | |
| SCHEMBL6360811 | 0.76 | CNR1 (0.55) | CNR1CNR2KDM4ENPC1RAB9A | |
| SCHEMBL1040785 | 0.73 | CNR1 (0.74) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2005061504-A1 | BICYCLIC PYRIDAZINONE CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885CHRNA7 142/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.